PET/CT in Evaluating Pediatric Malignancies: A Clinician’s Perspective

The introduction of combined CT with the functional imaging modality of PET has been an advancement in diagnostic imaging that has been welcomed by radiologists, nuclear medicine specialists, and oncologists. PET/CT has been used successfully in the diagnosis, staging, monitoring of response to therapy, and surveillance of various malignancies in adult patients (1,2). However, the role of PET/CT in the management of pediatric malignancies has not been well studied and, as a result, is less clearly defined in this population.

In this issue of The Journal of Nuclear Medicine, Tatsumi et al. report the use of PET/CT in the younger population in their retrospective study of 151 PET/CT examinations in 55 pediatric patients between 3 and 19 y old (3). The results of this study are especially convincing in patients with Hodgkin disease (HD) as most of the PET/CT was performed in these patients. The utility of PET/CT in the management of HD makes sense, particularly in the nodular sclerosing variety, which is so common in adolescents. In these patients, therapy may leave a patient with a fibrotic mass, which is still visible on CT or MRI. The ability of FDG PET to detect metabolic activity is very useful in differentiating between fibrotic scarring and residual active disease. These results have been corroborated in smaller studies of pediatric patients with HD and non-Hodgkin lymphoma (NHL). Rhodes et al. showed that PET/CT had a higher sensitivity, compared with CT alone, in evaluating patients for recurrent disease (4). Miller et al. demonstrated improved accuracy of staging with PET/CT in another small series of patients with lymphoma; there was a change in staging at the time of diagnosis in about one third of pediatric patients with HD and NHL (5).

There has been major improvement in the outlook for patients diagnosed with HD. The 5-y event-free survival (EFS) for children with favorable-prognosis HD is 85%–100% (6). Patients with more advanced disease have a 5-y EFS in the range of 70%–90% (6). Thus, a major focus of attention for pediatric HD has shifted to the long-term toxicities of our treatment strategies. This has led to a “risk-stratified” approach to the use of radiation therapy, anthracyclines, and alkylating agents (6). In the current Children’s Oncology Group trial, AHOD0031, using a risk-adapted approach to modify therapy in pediatric patients with HD, PET/CT has been instituted for diagnosis, staging, and response to therapy (7).

The utility of PET/CT in the diagnosis, staging, evaluation of response to therapy, and long-term follow-up of other nonlymphoma pediatric malignancies has not been adequately studied. Tatsumi et al. report the use of PET/CT in other pediatric malignancies in a group of 25 patients with bone and soft-tissue sarcomas, nasopharyngeal carcinomas, hepatoblastoma, ovarian cancer, and other malignancies (3). Although PET/CT may be helpful in the management of these various malignancies, the results of this study need to be repeated in larger trials that are histology specific.

The use of PET/CT can be helpful in the management of pediatric bone and soft-tissue sarcomas that demonstrate metabolic activity. It will assist in the identification of primary site, location of metastatic disease, and detection of recurrent disease. Thus, it will aid in the selection of therapeutic regimens and identify patients whose treatment needs adjustment. PET/CT has been particularly helpful in patients with inoperable sarcomas who have been treated with radiation for local control. This therapy may lead to scarring and fibrosis of bone and soft tissue that may be indistinguishable from persistent or recurrent disease without FDG PET to identify areas of hypermetabolic activity (8–10). Our experience has shown that the use of PET/CT in the management of Ewing sarcoma and osteosarcoma is useful in the initial staging period, response to therapy, and surveillance after chemotherapy in cases where 99mTc-methylene diphosphonate bone scintigraphy is negative and FDG PET/CT is positive on prior imaging. PET/CT may be useful in differentiating benign neurofibromas, usually metabolically inactive, from malignant peripheral nerve sheath tumors in patients with neurofibromatosis (11).

There has been much attention given to the long-term effects of the treatment of pediatric malignancies. These include development of cardiomyopathies, avascular necrosis of the hip, cognitive delay,
early onset of heart disease, and increased risk of secondary malignancies. Children who receive alkylating chemotherapy agents and radiation as part of their treatment regimens—such as in patients with HD and sarcoma—are at particular risk for developing secondary malignancies. The increasing use of not only PET/CT but also serial CT and plain-film radiography in the management of pediatric malignancies raises the important consideration of radiation exposure in children. This exposure is not trivial in patients with HD and sarcoma, who often get CT scans for 5 y as part of the surveillance for recurrent disease. It has been reported in numerous studies that children have an increased risk of developing secondary malignancies from radiation exposure compared with adults. In fact, by extrapolating data from atomic bomb survivors, this increased risk is by an order of magnitude greater than that of adults (12,13). It appears that this risk may be related to the greater life span of children and, hence, longer latency period to develop cancer. It has also been hypothesized that children have a greater proportion of actively dividing cells making them inherently more susceptible to radiation-induced damage. Consequently, radiation exposure from PET/CT in children should adhere to the ALARA principle (as low as reasonably achievable) to obtain diagnostic information (14).

The greatest contributor to overall radiation exposure in PET/CT is the whole-body diagnostic CT. In a study involving radiation exposure from whole-body FDG PET/CT in adults at 4 German institutions, the radiation dose from the diagnostic CT ranged from 14.1 to 18.6 mSv, the dose from CT topography ranged from 0.1 to 0.8 mSv, and the dose from FDG PET ranged from 5.7 to 7.0 mSv (15). The average total radiation dose of 25 mSv from 1 adult whole-body PET/CT in this study is roughly equivalent to 125 chest radiographs (at an average 0.2 mSv per radiograph) and is equivalent to exposure of 7 y of background radiation in an adult (16). In pediatrics, the radiation exposure from a standard PET/CT with diagnostic contrast-enhanced CT and CT topography for a 55-kg 15- y-old, a 20-kg 5- y-old, and a 10-kg 1-y-old is 21, 18, and 15 mSv, respectively. Using combined FDG PET/low-dose CT, the radiation exposure is reduced to 9 mSv in the 55-kg adolescent, 8 mSv in the 20-kg child, and 7 mSv in the 10-kg baby (17). However, it is not always possible or recommended to use low-dose CT for image attenuation in place of diagnostic spiral chest CT. This is particularly important in the staging of sarcoma patients, where FDG PET is less sensitive than spiral CT for the detection of pulmonary metastases (18).

From a clinical perspective, it is also important to keep in mind the feasibility of the PET/CT study in children. Young children may require anesthesia to keep still for the duration of the scan. The use of anesthesia in pediatrics is not without risk. A retrospective review of 16,467 pediatric sedations performed between 1997 and 2003 showed a 0.4% incidence of adverse respiratory events (19). In general, most children above the age of 5 y are able to undergo PET/CT examinations without the use of anesthesia. Franzius and Schober have reported that only 30% of 355 pediatric patients younger than 3/2 y required sedation to perform the PET/CT (20).

In summary, combined FDG PET/CT is a modality that may improve the evaluation and surveillance of pediatric malignancies. This has been shown convincingly by Tatsumi et al. (3). In HD and pediatric sarcomas, PET/CT appears to be an important tool in the management of these diseases. However, the use of PET/CT in other pediatric malignancies has yet to be rigorously studied. Furthermore, the timing, interval, and number of needed PET/CT scans in HD and sarcoma has not been clearly shown. Ongoing research is necessary to refine the ALARA principle in the use of PET/CT without sacrificing diagnostic information. Combined PET/MRI may be an option to reduce radiation exposure in the future. However, this may not be feasible because CT is superior to MRI in evaluation of lung parenchyma for metastatic disease, and children may require sedation for the extended duration of an MRI.

Noah Federman
Stephen A. Feig
Mattel Children’s Hospital
David Geffen School of Medicine at UCLA
Los Angeles, California

REFERENCES


